Calendula
PreclinicalSmall molecule
Calendula is one of 37 small molecule programs targeting Dermatitis. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Lapatinib Plus Capecitabine
GSKPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ibrance
PfizerPreclinical
Calendula
OOHSU Knight Cancer Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calendula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOHSU Knight Cancer Institute